Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan + FOLFOX in First-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT07490301Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Primary completion
- Jun 2031
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in pancreatic ductal adenocarcinoma (PDAC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Overall Response at 6 years and Overall Survival at 6 years. Started Apr 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07490301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490301.